Daewoong Pharmaceutical is actively engaged in the CP activities.
2024
Operation and Effectiveness Evaluation of the ISO 37001
Anti-Bribery Management System - Conducted the 2024 recertification audit for ISO 37001 and
successfully maintained the certification - All employees
signed company-wide pledges to comply with anti-bribery and fair
trade practices
Completed the preparation, retention, and submission of 2023
economic benefit expenditure reports to the Health Insurance
Review and Assessment Service (HIRA)
Promoted and provided training on the disclosure system for
expenditure reports
Continuously enhanced the economic benefit reporting system
Delivered CP (Compliance Program) training using multiple
channels, including offline sessions, online modules, and real-time
virtual training
Conducted information security campaigns and inspections of
office environments
Published CP Letters on a quarterly basis and actively promoted
key compliance messages
Completed competency-building education for compliance officers
and CP practitioners (CCP certification)
Implemented gift and entertainment campaigns, including the
message: "Do not give or receive holiday gifts"
Conducted continuous monitoring of product explanation meetings
Supported CP operations of affiliated group companies
Underwent regular CP audits conducted by partner companies(LG Chem, AstraZeneca Korea, and Lundbeck Korea)
2023
1st ex-post audit on ISO 27001 (information security)/ISO 27701
(personal information protection) international standard
certifications
1st ex-post audit on ISO 37001 (anti-bribery management system)
international standard certification (after certification renewal)
2022
Officers and employees company-wide sign the anti-corruption and
fair competition pledge (1,907 officers and employees)
General and intensive fair-competition training for new
transferees of the sales and marketing department for the first
half of the year (26 employees)
CP/anti-competition training for interns (16 interns)
Became the first company to simultaneously obtain
ISO27001(information security) and ISO27701(personal information
protection) certifications
Signed the 2022 Korean Association for Industrial Technology
Security Project for Enhancement of Security at Mid-Size
Enterprises and received government subsidies
Conducted due diligence on product information sessions and
symposia where lodging is provided
5th advanced development phase for the economic benefit and
expenditures reporting system (process automation and improved
monitoring efficiency)
General and intensive fair-competition training for new
transferees of the sales and marketing department for the second
half of the year
Received a regular CP audit for LG Life Sciences partners
Received a regular CP audit for AstraZeneca Korea partners
Regular update of the 2022 company-wide corruption risk assessment
report
Conducted 2022 internal audit on anti-corruption management
(random selection of 36 teams from headquarters, research center,
and factories)
2022 Anti-corruption CEO management review report
Anti-corruption training for all employees (1,847 persons)
2021
24th amendment to CP SOP
Conducted anti-corruption and CP training for all employees for
2021
Conducted training and instruction of marketing department
personnel on rebate prevention and fair competition (completed by
413 employees)
Provided general and intensive instructions on fair competition
for newly transferred members of the sales and marketing
department (completed by 20 employees)
ISO37001 certification renewed
Continuing education and renewal of certification for certified
compliance professionals (CCPs) (current number of certified
professionals: 7 Class I professionals, 1 Class II professional)